Clinical trial
Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease
NCT02743806 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease
- Lead sponsor
- Takeda
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- August 1, 2016
- Completion date
- January 3, 2023
- Enrollment
- 331 (actual)
- Sites
- 78
Conditions
As the registry lists them; a condition with its own page is linked.